Skip to content
Triangle logo TriangleGet started
← Non-Small Cell Lung Cancer

HEALTH PROFESSIONAL · SOURCE READING

RET inhibitors (for patients with RET fusions)

Source: Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 15, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Progressive Stage IV, Relapsed, and Recurrent NSCLC / Treatment Options for Progressive Stage IV, Relapsed, and Recurrent NSCLC (Second-Line Therapy)

Somatic gene fusions of RET occur in 1% to 2% of patients with NSCLC and in patients with thyroid cancer.[51]

Source links and citations

Continue within this section

Selpercatinib →Pralsetinib →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice